SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention over the wait for the 80th overall-survival event in its Phase 3 REGAL AML trial and the companys quiet period; the last reported count was 78, and no new result is confirmed. Bulls view the prolonged wait as a possible sign of extended survival on GPS, while bears question the trial and disclosure timeline, and the selloff has fueled debate over whether market and options pressure or company-specific concerns are driving the move.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has dominated discussion, pushing back against widespread Black Monday crash fears. Bulls view the move as a relief rally or short squeeze, while skeptics call it a low-volume bull trap and question whether it will hold; some traders also speculate that Russia-related diesel and peace-talk headlines are helping sentiment.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp tech- and AI-linked selloff followed by a strong futures rebound, with traders split over whether the bounce signals recovery or is a short-covering rally that could fade. Crash warnings, including Black Monday talk, are competing with optimism ahead of major tech earnings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor-sector selloff and volatile rebound, with traders debating whether the bounce marks a bottom or is a temporary rally. The bearish case centers on worries about AI spending, debt, inflation and Chinese competition, while dip buyers point to continued chip demand and the sectors oversold condition.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention amid a sharp selloff across semiconductor and AI-linked stocks, with traders debating whether concerns about AI spending, inflation and broader market risk point to further weakness or an oversold pullback. Bulls point to Intels foundry prospects and upcoming earnings, while bears question its valuation and warn the selling may continue.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on lifileucel is driving attention: traders are weighing mature frontline melanoma results and early sarcoma responses as encouraging signs, while noting the small cohorts and need for confirmation in larger trials. The sharp pullback is widely viewed in the discussion as part of broader biotech and market weakness rather than a clear company-specific reaction.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

CBRS is under pressure amid concern that IPO lockup expirations could add selling supply, alongside a broader AI and semiconductor selloff and worries about its valuation. Traders are split between expecting further declines and buying the dip, with bullish posts pointing to demand for Cerebras AI inference systems and capacity constraints.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across neocloud and AI-infrastructure stocks, driven by worries about debt, financing costs, and whether heavy data-center spending will pay off, is weighing on Nebius. Traders are divided: bears see more downside as the sector faces a valuation reset, while bulls argue Nebius is financially stronger than some peers and the pullback is overdone.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs move lower is centered on Neutrons first launch slipping to 2027 after manufacturing defects were found in a carbon-composite tank component. Traders are split between viewing the delay as a prudent safety decision and seeing it as a setback to execution, credibility, and the timing of future launch revenue.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

A sharp AI-sector selloff and concerns about Super Micros governance and export-control risks are driving attention as the stock posts steep losses. Bulls call the decline an oversold buying opportunity and point to expected earnings and AI demand, while bears worry about compliance issues, management credibility, and a possible slowdown in AI spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intuitive Surgical (ISRG) Stock Is Down 25% Year to Date. History Says Patient Investors Get Rewarded.

Key PointsIntuitive Surgical is a dominant force in robotic surgery systems...

Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside 

Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels heading into its Q3 earnings release on October 20.

If You Invested $1000 In Intuitive Surgical Stock 10 Years Ago, You Would Have This Much Today

Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 5.33% on an annualized basis producing an average annual return of 19.01%. Currently, Intuitive Surgical has a market capitalizationread more...

First Week of Q3 Earnings in the Books

The Dow looks to close higher for its second-straight week, while the Nasdaq hopes to avoid its worst trading week since July.

ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?

Intuitive Surgical's Q3 earnings hinge on robotic surgery growth, system demand and margins amid slowing US procedures, China headwinds and premium valuation.

Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know

Intuitive Surgical, Inc. (ISRG) reached $427.86 at the closing of the latest trading day, reflecting a +1.81% change compared to its last close.

Countdown to Intuitive Surgical (ISRG) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Evaluate the expected performance of Intuitive Surgical (ISRG) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

ISRG Gains Nearly 12% in a Month: Should You Buy, Hold or Sell?

Intuitive Surgical shares have surged nearly 12% in a month ahead of Q3 earnings. Strong da Vinci 5 adoption and Ion growth fuel momentum, but valuation and risks linger.

Zacks.com featured highlights include Chipotle Mexican Grill, BP and Intuitive Surgical

Chipotle, BP and Intuitive Surgical stand out as sales growth stocks to watch, with 2026 revenue forecasts ranging from 9% to 28.9% as Q3 earnings begin.

ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters

Intuitive Surgical is targeting GI care with a next-generation robotic endoscope submitted to the FDA, opening a potential growth avenue beyond surgery.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Why Did PEGA, ISRG, MCD Stocks Plunge To 52-Week Lows Today? 

Equity

Neutral Sentiment

$NBIS

$APLD

$AMD

$ISRG

$NBIS, $APLD, $AMD, and $ISRG are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish on? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 5 years - $NBIS, $APLD, $AMD, or $ISRG?

Current Price	$426.70
Prev Close	$427.86
Open	$428.43
Dividend Yield	0.00%
50-Day Moving Average	$391.67
Beta	1.15
Avg. Volume	2.41M
PE Ratio	48.90

52-Week High	$603.88
52-Week Low	$328.57
Market Capitalization	$150.74B
EPS (Annual)	$7.87
Price to Book	8.31
Revenue Per Employee	$591,310.73

Feed

News

Sentiment

Earnings

Fundamentals

Info

ISRG Fundamentals